GeneDx to Participate in Upcoming Investor Conferences

GeneDx (Nasdaq: WGS), a leader in rare disease diagnosis and genomic data utilization, has announced its upcoming participation in two prominent investor conferences. The TD Cowen 46th Annual Health Care Conference will be held in Boston, MA, where GeneDx management will engage in a fireside chat on March 2 at 1:50 PM ET. Following this, the company will be represented at the Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, with a presentation scheduled for March 11 at 3:00 PM ET. Investors and interested parties can access live and archived webcasts of these discussions on the "Events" section of GeneDx’s investor relations website.

GeneDx aims to empower individuals to lead healthier lives through genomics. The company distinguishes itself through its robust clinical expertise and advanced technology, leveraging GeneDx Infinity™, the largest genomic dataset focused on rare diseases. This foundation supports GeneDx’s innovative ExomeDx™ and GenomeDx™ tests, which are recognized as top-tier by genetic experts and have received FDA Breakthrough Device designation, enabling rapid and effective diagnoses. Additionally, GeneDx Infinity™ drives biopharmaceutical discoveries using advanced AI-powered genomic intelligence.

With over 25 years in the field, GeneDx has diagnosed more than 4,800 genetic diseases and has contributed over 1,000 research publications, illustrating its commitment to enhancing genomic precision medicine. For further details, stakeholders can visit the company’s website or connect via social media platforms like LinkedIn, Facebook, and Instagram.

For investor inquiries, you can contact GeneDx at Investors@GeneDx.com, and for media-related questions, reach out to Press@GeneDx.com.

As GeneDx (Nasdaq: WGS) gears up for its participation in prominent investor conferences—namely the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference—it presents an opportune moment for investors to reassess the company's position within the burgeoning field of genomic medicine.

GeneDx is recognized for its pioneering work in rare disease diagnostics, leveraging its GeneDx Infinity™ dataset and advanced genomic testing capabilities. The company's unique offerings, such as the ExomeDx™ and GenomeDx™ tests, have garnered significant recognition, including FDA Breakthrough Device designation, signaling strong regulatory endorsement. This reinforces GeneDx's ability to deliver rapid and actionable diagnostic solutions that are crucial for clinicians and patients alike.

Investors should closely monitor the presentations at these conferences, as they will likely provide strategic insights into the company's future direction, product pipeline, and potential partnerships within the biopharma sector. The financial commitments and strategic partnerships that arise from these interactions can significantly enhance GeneDx's market position.

Given its strong foundation supported by over 25 years of expertise and a vast array of published research, GeneDx is well-positioned to capitalize on the increasing demand for genomic data solutions in health care. As the sector transitions toward more personalized medicine, GeneDx’s capabilities in AI-driven genomic intelligence may yield substantial returns.

For prospective investors, attending the live webcasts or following up on the archived sessions could enhance understanding of the company’s strategies and growth potential. Given the rising trend in genomic research and applications, investing in GeneDx might not only align with a growing industry but also present a resilient opportunity for long-term growth.